Skip to Content

Acalabrutinib Shows Lower Cardiac Failure Rates Than Ibrutinib in CLL Treatment

The first-generation BTK inhibitor, ibrutinib, is known to increase the risk of cardiac arrhythmias and heart failure. To address this concern, a study examined heart failure occurrence in CLL patients treated with the second-generation BTK inhibitor, acalabrutinib. Paolo Ghia, Professor at Università Vita-Salute San Raffaele in Italy, shares the trial results in this EHA23 MEDtalk, that provides insights into the cardiac safety of acalabrutinib.

Paolo Ghia

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top